胆汁酸代谢在原发性胆汁性胆管炎发病机制中的作用

贾皖婷; 刘晓晓; 邰文琳

doi:10.3969/j.issn.1001-5256.2022.10.031

胆汁酸代谢在原发性胆汁性胆管炎发病机制中的作用

DOI: 10.3969/j.issn.1001-5256.2022.10.031

昆明医科大学第二附属医院检验科，昆明 650032

基金项目:

国家自然科学基金 (82060385)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：贾皖婷负责文献查找、阅读及文章撰写; 刘晓晓对研究思路有关键贡献; 邰文琳负责文章修改。

详细信息

通信作者:
邰文琳，taiwenlinlin@sohu.com

计量
- 文章访问数: 431
- HTML全文浏览量: 115
- PDF下载量: 84
- 被引次数: 0
出版历程
- 收稿日期: 2022-03-01
- 录用日期: 2022-04-15
- 出版日期: 2022-10-20

Role of bile acid metabolism in the pathogenesis of primary biliary cholangitis

Department of Clinical Laboratory, The Second Affiliated Hospital of Kunming Medical University, Kunming 650032, China

Research funding:

National Natural Science Foundation of China (82060385)

More Information

Corresponding author: TAI Wenlin, taiwenlinlin@sohu.com(ORCID: 0000-0002-8278-929X)

摘要

摘要: 原发性胆汁性胆管炎(PBC)是一种胆汁淤积性自身免疫性肝病, 以中老年女性高发, 小胆管淋巴细胞浸润和胆汁淤积为主要特征。临床表现以疲惫和胆汁淤积造成的瘙痒为主。目前被批准的治疗药物熊去氧胆酸和奥贝胆酸, 主要是通过调节胆汁酸代谢，特异且有效的改善胆汁淤积而起作用。本文介绍了胆汁酸生理及疾病状态下的病理改变，归纳了胆汁酸代谢参与疾病发病机制的可能方式，总结了目前针对胆汁酸代谢的疾病治疗方法。指出PBC胆汁酸代谢改变主要与阴离子交换器2缺陷、胆汁酸代谢的转运体和核受体先天遗传变异及后天适应性改变、肠道菌群结构发生改变有关。
- 原发性胆汁性胆管炎 /
- 胆汁酸类和盐类 /
- 病理过程
Abstract: Primary biliary cholangitis (PBC) is a cholestatic autoimmune liver disease characterized by a high incidence rate in middle-aged and elderly women, lymphocyte infiltration in small bile ducts, and cholestasis. Main clinical manifestations include fatigue and pruritus caused by cholestasis. Ursodeoxycholic acid and obeticholic acid are currently approved therapeutic drugs for PBC and exert a therapeutic effect by regulating bile acid metabolism and specifically and effectively improving cholestasis. This article introduces the physiological and pathological changes of bile acids in disease states and summarizes the possible ways in which bile acid metabolism is involved in the pathogenesis of diseases and the current treatment methods for bile acid metabolism. It is pointed out that the changes of bile acid metabolism in PBC are mainly associated with anion exchanger 2 deficiency, innate genetic variation and acquired adaptive changes of bile acid metabolism transporters and nuclear receptors, and changes in the structure of intestinal flora.
- Primary Biliary Cholangitis /
- Bile Acids and Salts /
- Pathologic Processes

HTML全文

参考文献(54)

[1]	LLEO A, WANG GQ, GERSHWIN ME, et al. Primary biliary cholangitis[J]. Lancet, 2020, 396(10266): 1915-1926. DOI: 10.1016/S0140-6736(20)31607-X.
[2]	TRIVEDI PJ, HIRSCHFIELD GM. Recent advances in clinical practice: epidemiology of autoimmune liver diseases[J]. Gut, 2021, 70(10): 1989-2003. DOI: 10.1136/gutjnl-2020-322362.
[3]	ZENG N, DUAN W, CHEN S, et al. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis[J]. Hepatol Int, 2019, 13(6): 788-799. DOI: 10.1007/s12072-019-09984-x.
[4]	TERZIROLI BERETTA-PICCOLI B, MIELI-VERGANI G, VERGANI D, et al. The challenges of primary biliary cholangitis: What is new and what needs to be done[J]. J Autoimmun, 2019, 105: 102328. DOI: 10.1016/j.jaut.2019.102328.
[5]	GULAMHUSEIN AF, HIRSCHFIELD GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(2): 93-110. DOI: 10.1038/s41575-019-0226-7.
[6]	HANG S, PAIK D, YAO L, et al. Bile acid metabolites control TH17 and Treg cell differentiation[J]. Nature, 2019, 576(7785): 143-148. DOI: 10.1038/s41586-019-1785-z.
[7]	SONG X, SUN X, OH SF, et al. Microbial bile acid metabolites modulate gut RORγ⁺ regulatory T cell homeostasis[J]. Nature, 2020, 577(7790): 410-415. DOI: 10.1038/s41586-019-1865-0.
[8]	XIANG J, ZHANG Z, XIE H, et al. Effect of different bile acids on the intestine through enterohepatic circulation based on FXR[J]. Gut Microbes, 2021, 13(1): 1949095. DOI: 10.1080/19490976.2021.1949095.
[9]	WANG Y, LI J, MATYE D, et al. Bile acids regulate cysteine catabolism and glutathione regeneration to modulate hepatic sensitivity to oxidative injury[J]. JCI Insight, 2018, 3(8): e99676. DOI: 10.1172/jci.insight.99676.
[10]	JUNG H, CHEN J, HU X, et al. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination[J]. JCI Insight, 2020, 6(1): e141640. DOI: 10.1172/jci.insight.141640.
[11]	XIE C, TAKAHASHI S, BROCKER CN, et al. Hepatocyte peroxisome proliferator-activated receptor α regulates bile acid synthesis and transport[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2019, 1864(10): 1396-1411. DOI: 10.1016/j.bbalip.2019.05.014.
[12]	JONES D, BOUDES PF, SWAIN MG, et al. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study[J]. Lancet Gastroenterol Hepatol, 2017, 2(10): 716-726. DOI: 10.1016/S2468-1253(17)30246-7.
[13]	ENHANCE: Safety and efficacy of seladelpar in patients with primary biliary cholangitis-a phase 3, international, randomized, placebo-controlled study[J]. Gastroenterol Hepatol (N Y), 2021, 17(2 Suppl 3): 5-6.
[14]	KREMER AE, MAYO MJ, HIRSCHFIELD G, et al. Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis[J]. Liver Int, 2022, 42(1): 112-123. DOI: 10.1111/liv.15039.
[15]	XU BY, TANG XD, CHEN J, et al. Rifampicin induces clathrin-dependent endocytosis and ubiquitin-proteasome degradation of MRP2 via oxidative stress-activated PKC-ERK/JNK/p38 and PI3K signaling pathways in HepG2 cells[J]. Acta Pharmacol Sin, 2020, 41(1): 56-64. DOI: 10.1038/s41401-019-0266-0.
[16]	SONODA J, CHONG LW, DOWNES M, et al. Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites[J]. Proc Natl Acad Sci U S A, 2005, 102(6): 2198-2203. DOI: 10.1073/pnas.0409481102.
[17]	KHURANA S, SINGH P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials[J]. Liver Int, 2006, 26(8): 943-948. DOI: 10.1111/j.1478-3231.2006.01326.x.
[18]	SULTANA H, KOMAI M, SHIRAKAWA H. The role of vitamin K in cholestatic liver disease[J]. Nutrients, 2021, 13(8): 2515. DOI: 10.3390/nu13082515.
[19]	ZHANG Z, CHEN F, LI J, et al. 1, 25(OH)2D3 suppresses proinflammatory responses by inhibiting Th1 cell differentiation and cytokine production through the JAK/STAT pathway[J]. Am J Transl Res, 2018, 10(8): 2737-2746.
[20]	FANG F, WANG J, PAN J, et al. Relationship between vitamin D (1, 25-dihydroxyvitamin D3) receptor gene polymorphisms and primary biliary cirrhosis risk: a meta-analysis[J]. Genet Mol Res, 2015, 14(1): 981-988. DOI: 10.4238/2015.February.6.1.
[21]	KEMPINSKA-PODHORODECKA A, MILKIEWICZ M, WASIK U, et al. Decreased expression of vitamin D receptor affects an immune response in primary biliary cholangitis via the VDR-miRNA155-SOCS1 pathway[J]. Int J Mol Sci, 2017, 18(2): 289. DOI: 10.3390/ijms18020289.
[22]	GONZALEZ-SANCHEZ E, EL MOURABIT H, JAGER M, et al. Cholangiopathy aggravation is caused by VDR ablation and alleviated by VDR-independent vitamin D signaling in ABCB4 knockout mice[J]. Biochim Biophys Acta Mol Basis Dis, 2021, 1867(4): 166067. DOI: 10.1016/j.bbadis.2020.166067.
[23]	VASSILEVA G, GOLOVKO A, MARKOWITZ L, et al. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation[J]. Biochem J, 2006, 398(3): 423-430. DOI: 10.1042/BJ20060537.
[24]	FIORUCCI S, DISTRUTTI E, CARINO A, et al. Bile acids and their receptors in metabolic disorders[J]. Prog Lipid Res, 2021, 82: 101094. DOI: 10.1016/j.plipres.2021.101094.
[25]	SANG C, WANG X, ZHOU K, et al. Bile acid profiles are distinct among patients with different etiologies of chronic liver disease[J]. J Proteome Res, 2021, 20(5): 2340-2351. DOI: 10.1021/acs.jproteome.0c00852.
[26]	CHEN W, WEI Y, XIONG A, et al. Comprehensive analysis of serum and fecal bile acid profiles and interaction with gut microbiota in primary biliary cholangitis[J]. Clin Rev Allergy Immunol, 2020, 58(1): 25-38. DOI: 10.1007/s12016-019-08731-2.
[27]	PRIETO J, QIAN C, GARCÍA N, et al. Abnormal expression of anion exchanger genes in primary biliary cirrhosis[J]. Gastroenterology, 1993, 105(2): 572-578. DOI: 10.1016/0016-5085(93)90735-u.
[28]	MEDINA JF, MARTÍNEZ-ANSÓ, VAZQUEZ JJ, et al. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis[J]. Hepatology, 1997, 25(1): 12-17. DOI: 10.1002/hep.510250104.
[29]	BANALES JM, SÁEZ E, URIZ M, et al. Up-regulation of microRNA 506 leads to decreased Cl^-/HCO₃^- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis[J]. Hepatology, 2012, 56(2): 687-697. DOI: 10.1002/hep.25691.
[30]	RODRIGUES PM, PERUGORRIA MJ, SANTOS-LASO A, et al. Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?[J]. J Hepatol, 2018, 69(6): 1371-1383. DOI: 10.1016/j.jhep.2018.08.020.
[31]	HISAMOTO S, SHIMODA S, HARADA K, et al. Hydrophobic bile acids suppress expression of AE2 in biliary epithelial cells and induce bile duct inflammation in primary biliary cholangitis[J]. J Autoimmun, 2016, 75: 150-160. DOI: 10.1016/j.jaut.2016.08.006.
[32]	KOJIMA H, NIES AT, KÖNIG J, et al. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis[J]. J Hepatol, 2003, 39(5): 693-702. DOI: 10.1016/s0168-8278(03)00410-0.
[33]	INAMINE T, HIGA S, NOGUCHI F, et al. Association of genes involved in bile acid synthesis with the progression of primary biliary cirrhosis in Japanese patients[J]. J Gastroenterol, 2013, 48(10): 1160-1170. DOI: 10.1007/s00535-012-0730-9.
[34]	PHAM DH, KUDIRA R, XU L, et al. Deleterious variants in ABCC12 are detected in idiopathic chronic cholestasis and cause intrahepatic bile duct loss in model organisms[J]. Gastroenterology, 2021, 161(1): 287-300. e16. DOI: 10.1053/j.gastro.2021.03.026.
[35]	AFONSO MB, RODRIGUES PM, SIMÃO AL, et al. miRNA-21 ablation protects against liver injury and necroptosis in cholestasis[J]. Cell Death Differ, 2018, 25(5): 857-872. DOI: 10.1038/s41418-017-0019-x.
[36]	JUANOLA O, HASSAN M, KUMAR P, et al. Intestinal microbiota drives cholestasis-induced specific hepatic gene expression patterns[J]. Gut Microbes, 2021, 13(1): 1-20. DOI: 10.1080/19490976.2021.1911534.
[37]	WANG D, DOESTZADA M, CHEN L, et al. Characterization of gut microbial structural variations as determinants of human bile acid metabolism[J]. Cell Host Microbe, 2021, 29(12): 1802-1814. e5. DOI: 10.1016/j.chom.2021.11.003.
[38]	LI Y, TANG R, LEUNG P, et al. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases[J]. Autoimmun Rev, 2017, 16(9): 885-896. DOI: 10.1016/j.autrev.2017.07.002.
[39]	HARUTA I, HASHIMOTO E, KATO Y, et al. Lipoteichoic acid may affect the pathogenesis of bile duct damage in primary biliary cirrhosis[J]. Autoimmunity, 2006, 39(2): 129-135. DOI: 10.1080/08916930600623841.
[40]	TANG R, WEI Y, LI Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J]. Gut, 2018, 67(3): 534-541. DOI: 10.1136/gutjnl-2016-313332.
[41]	LI B, ZHANG J, CHEN Y, et al. Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary cholangitis[J]. Gut Microbes, 2021, 13(1): 1946366. DOI: 10.1080/19490976.2021.1946366.
[42]	HARMS MH, VAN BUUREN HR, CORPECHOT C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis[J]. J Hepatol, 2019, 71(2): 357-365. DOI: 10.1016/j.jhep.2019.04.001.
[43]	XIA ZY, HAN T, MENG HJ. Clinical efficacy of early stage immunosuppression combined with ursodeoxycholic acid in the treatment of primary biliary cirrhosis[J]. Clin J Med Offic, 2020, 48(1): 97-98, 101. DOI: 10.16680/j.1671-3826.2020.01.33. 夏志勇, 韩涛, 孟红军. 早期免疫抑制联合熊去氧胆酸治疗原发性胆汁性肝硬化临床疗效[J]. 临床军医杂志, 2020, 48(1): 97-98, 101. DOI: 10.16680/j.1671-3826.2020.01.33.
[44]	KULKARNI AV, TEVETHIA HV, ARAB JP, et al. Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2021, 45(3): 101675. DOI: 10.1016/j.clinre.2021.101675.
[45]	KJÆRGAARD K, FRISCH K, SØRENSEN M, et al. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis[J]. J Hepatol, 2021, 74(1): 58-65. DOI: 10.1016/j.jhep.2020.07.028.
[46]	GOMEZ E, GARCIA BUEY L, MOLINA E, et al. Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid[J]. Aliment Pharmacol Ther, 2021, 53(4): 519-530. DOI: 10.1111/apt.16181.
[47]	VERBEKE L, NEVENS F, LALEMAN W. Steroidal or non-steroidal FXR agonists - Is that the question?[J]. J Hepatol, 2017, 66(4): 680-681. DOI: 10.1016/j.jhep.2017.01.013.
[48]	JOHN BV, SCHWARTZ K, LEVY C, et al. Impact of obeticholic acid exposure on decompensation and mortality in primary biliary cholangitis and cirrhosis[J]. Hepatol Commun, 2021, 5(8): 1426-1436. DOI: 10.1002/hep4.1720.
[49]	CHEN J, GU J, SHAH B, et al. Pharmacokinetics of tropifexor, a potent farnesoid X receptor agonist, in participants with varying degrees of hepatic impairment[J]. J Clin Pharmacol, 2022, 62(4): 520-531. DOI: 10.1002/jcph.1996.
[50]	FENG BL, YU HH, SHEN W. Ursodeoxycholic acid combined with bezafibrate in the treatment of refractory primary biliary cholangitis: a meta-analysis[J]. Chin J Hepatol, 2019, 27(4): 304-311. DOI: 10.3760/cma.j.issn.1007-3418.2019.04.012. 奉白蕾, 俞慧宏, 沈薇. 熊去氧胆酸联合苯扎贝特治疗难治性原发性胆汁性胆管炎的Meta分析[J]. 中华肝脏病杂志, 2019, 27(4): 304-311. DOI: 10.3760/cma.j.issn.1007-3418.2019.04.012.
[51]	SCHATTENBERG JM, PARES A, KOWDLEY KV, et al. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA[J]. J Hepatol, 2021, 74(6): 1344-1354. DOI: 10.1016/j.jhep.2021.01.013.
[52]	KIM KY, MANCANO MA. Fenofibrate potentiates warfarin effects[J]. Ann Pharmacother, 2003, 37(2): 212-215. DOI: 10.1177/106002800303700210.
[53]	FILIPPATOS TD, ELISAF MS. Safety considerations with fenofibrate/simvastatin combination[J]. Expert Opin Drug Saf, 2015, 14(9): 1481-1493. DOI: 10.1517/14740338.2015.1056778.
[54]	GHONEM NS, ASSIS DN, BOYER JL. Fibrates and cholestasis[J]. Hepatology, 2015, 62(2): 635-643. DOI: 10.1002/hep.27744.